Equities

Advanced Enzyme Technologies Ltd

ADVENZYMES:NSI

Advanced Enzyme Technologies Ltd

Actions
Basic MaterialsChemicals
  • Price (INR)395.40
  • Today's Change-0.10 / -0.03%
  • Shares traded171.51k
  • 1 Year change+43.68%
  • Beta0.5262
Data delayed at least 15 minutes, as of May 03 2024 10:51 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Advanced Enzyme Technologies Limited is an India-based company, engaged in manufacturing enzymes and probiotics. The Company is focused on the research and development, manufacturing, and marketing of approximately 400 products, which is developed from over 68 indigenous enzymes and probiotics. It provides solutions to various industries, such as human health care and nutrition, animal nutrition, baking, fruit, and vegetable processing, brewing, and malting, grain processing, protein modification, dairy processing, textile processing and others. It offers products and solutions for human nutrition, which include serratiopeptidase, fungal lactase, fungal lipase, and papain; animal nutrition, which include DigeGrain X, DigeGrain XL and DigeGrain M; food processing, including dairy and cheese processing and yeast processing, and non-food processing, including textiles processing, leather, and biofuels. Its oils and fats processing include oil extraction, oil refining, and others.

  • Revenue in INR (TTM)6.05bn
  • Net income in INR1.37bn
  • Incorporated1989
  • Employees338.00
  • Location
    Advanced Enzyme Technologies LtdSun-Magnetica, A Wing, 5th FloorLIC Service Road, LouiswadiTHANE 400604IndiaIND
  • Phone+91 2 241703200
  • Fax+91 2 225835159
  • Websitehttps://www.advancedenzymes.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Morepen Laboratories Ltd16.31bn761.19m25.71bn1.65k33.33--24.041.581.511.5132.53--------9,891,111.00--7.39--13.7835.8532.824.675.19--27.34--0.00-8.3618.51-61.965.5011.33--
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn25.88bn1.23k--81.85----------12.72------------------------0.8228--0.2681--43.84--77.37------
Innova Captab Ltd-100.00bn-100.00bn26.62bn--------------------------------------------------15.72--6.26------
SeQuent Scientific Ltd13.75bn-1.29bn30.46bn478.00------2.22-5.18-5.1855.33--------28,769,920.00--2.33--3.6742.7842.47-8.972.59---0.3894--17.270.572810.84-395.83--12.88--
Indoco Remedies Ltd17.96bn1.02bn30.55bn6.10k30.32--16.591.7010.9310.93192.26--------2,943,454.00--6.07--8.9069.3965.355.616.30--5.11--14.798.309.81-8.1128.158.2517.61
Gufic BioSciences Ltd7.85bn841.95m33.09bn1.63k38.28--31.374.228.628.6280.38--------4,820,074.00--12.30--23.0851.0844.9110.739.84--8.22--1.39-11.3617.47-16.8437.0686.8214.87
Supriya Lifescience Ltd5.54bn1.20bn33.69bn392.0027.96--24.906.0814.9714.9768.93--------14,144,410.00--20.77--29.0661.9455.8321.7224.33--63.63--2.02-13.0416.70-40.8159.4185.55--
Dishman Carbogen Amcis Ltd25.80bn-1.54bn36.08bn1.30k----24.491.40-9.84-9.84164.35--------19,919,850.00--0.4699--0.566576.9374.36-5.981.82---0.1245--202.7612.727.32-265.46--21.54--
Hikal Ltd18.16bn716.22m37.38bn2.14k52.24--20.352.065.805.80147.17--------8,477,077.00--5.86--8.8752.0845.413.946.37--2.78--10.144.139.25-51.160.297323.354.42
Unichem Laboratories Ltd16.75bn145.69m41.21bn3.12k283.30--31.622.462.072.07234.69--------5,364,373.00---1.38---1.6659.9456.150.8696-3.60---0.9613----5.7610.51-711.67---22.60--
Advanced Enzyme Technologies Ltd6.05bn1.37bn44.23bn338.0032.21--25.487.3112.2812.2854.16--------17,892,400.00--11.87--13.1976.4272.2023.0225.79--59.04--7.492.136.44-11.663.2428.3214.87
Aarti Drugs Ltd26.51bn1.80bn46.04bn1.50k25.65--19.951.7419.5219.52287.30--------17,673,360.00--9.91--16.4032.2522.336.818.23--8.29--5.539.1416.56-18.8915.1117.2031.95
Aarti Pharmalabs Ltd18.32bn1.95bn46.45bn1.40k23.88--17.562.5421.4721.47202.17--------13,085,090.00--------42.00--10.62----16.14----62.11--58.27------
Orchid Pharma Ltd8.12bn1.25bn53.74bn838.0037.18--33.816.6228.5026.84175.33--------9,691,729.00---1.07---1.9641.4945.8715.63-3.52--4.34----19.00-0.6456187.87--68.72--
Shilpa Medicare Ltd11.23bn-6.71m54.21bn1.03k----50.984.83-0.0714-0.0714131.44--------10,873,050.00--3.89--4.9264.4260.22-0.05389.29--1.16--10.65-8.335.82-153.54--14.58--
Data as of May 03 2024. Currency figures normalised to Advanced Enzyme Technologies Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

6.52%Per cent of shares held by top holders
HolderShares% Held
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Mar 20244.10m3.67%
ICICI Prudential Asset Management Co. Ltd.as of 31 Mar 20241.97m1.77%
Dimensional Fund Advisors LPas of 04 Apr 2024611.07k0.55%
BlackRock Fund Advisorsas of 04 Apr 2024177.51k0.16%
BlackRock Advisors (UK) Ltd.as of 02 Apr 2024159.37k0.14%
Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 202470.87k0.06%
SSgA Funds Management, Inc.as of 04 Apr 202464.01k0.06%
Dimensional Fund Advisors Ltd.as of 29 Feb 202458.30k0.05%
TIAA-CREF Investment Management LLCas of 29 Feb 202445.11k0.04%
State Board of Administration of Florida Retirement Systemas of 30 Jun 202323.00k0.02%
More ▼
Data from 31 Dec 2023 - 25 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.